Johnson & Johnson today confirmed reports it is engaged in initial conversations with Actelion Pharmaceuticals “regarding a potential transaction.”

Johnson & Johnson (NYSE:JNJ) today confirmed reports it is engaged in initial conversations with Actelion Pharmaceuticals “regarding a potential transaction.”
According to the press release,

“There can be no assurance any transaction will result from these discussions. Johnson & Johnson does not intend to make any additional comments regarding these discussions unless and until it is appropriate to do so, or a formal agreement has been reached.”

Read the full press release here.